Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $32.50.

A number of equities analysts recently issued reports on the stock. Guggenheim decreased their price target on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Wells Fargo & Company reduced their target price on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. JPMorgan Chase & Co. increased their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th.

Insider Buying and Selling

In related news, COO Jennifer Champoux sold 2,175 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares of the company’s stock, valued at $1,247,420. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Philip Nickson sold 5,845 shares of Monte Rosa Therapeutics stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $17.69, for a total value of $103,398.05. Following the transaction, the insider owned 55,000 shares of the company’s stock, valued at $972,950. The trade was a 9.61% decrease in their position. The SEC filing for this sale provides additional information. 6.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Hedge funds have recently bought and sold shares of the company. State Street Corp increased its stake in Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after purchasing an additional 1,260,707 shares in the last quarter. MPM Bioimpact LLC bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter worth approximately $18,399,000. AQR Capital Management LLC grew its holdings in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares during the last quarter. Braidwell LP purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $14,870,000. Finally, Vestal Point Capital LP bought a new stake in shares of Monte Rosa Therapeutics during the third quarter valued at approximately $5,928,000. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE opened at $16.61 on Wednesday. Monte Rosa Therapeutics has a fifty-two week low of $4.12 and a fifty-two week high of $25.77. The stock has a market cap of $1.40 billion, a P/E ratio of -11.22 and a beta of 1.60. The stock has a 50 day simple moving average of $18.49 and a two-hundred day simple moving average of $18.37.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Sell-side analysts predict that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.